Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Absci Corp (NQ: ABSI )

2.590 +0.040 (+1.57%)
Streaming Delayed Price Updated: 12:48 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Absci Corp

< Previous 1 2 3 4 5 6 7 Next >
Absci to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Absci Corporation
Via GlobeNewswire
A $50B AI Drug Discovery Revolution Has Begun - Here Are 6 Stocks To Consider Investing In
The drug development process is very expensive and time-consuming which creates a huge shortage in drug candidates and programs but the advent of AI can significantly shorten and cheapen this process... 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
The Analyst Verdict: Absci In The Eyes Of 6 Experts
Via Benzinga
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q1 2024
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
6 Analysts Assess Absci: What You Need To Know
Via Benzinga
Absci: Q4 Earnings Insights
Via Benzinga
The Analyst Landscape: 4 Takes On Absci
Via Benzinga
Absci Reports Business Updates and First Quarter 2024 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May
We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD. 
Via Talk Markets
Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week
A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and... 
Via Talk Markets
All 7 AI Category Portfolios Continued To Decline This Week
All 54 AI stocks in the 7 AI category portfolios dropped this week, down 8.4%, on average, making it clear that the surge in the AI sector that began back on October 31st is over. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Absci (ABSI) Shares Are Falling
Absci shares are trading lower by 9.4% Wednesday afternoon. The company announced an offering of 16.7 million shares at $4.50 per share. 
Via Benzinga
Absci to Report Business Updates and First Quarter 2024 Financial and Operating Results on May 14, 2024
From Absci Corporation
Via GlobeNewswire
BlackBerry, Nurix Therapeutics, Tesla And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSE: BB) rose sharply during Tuesday’s session. 
Via Benzinga
Topics Stocks
Exposures US Equities
Absci to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Absci Corporation
Via GlobeNewswire
ABSI Stock Earnings: Absci Misses EPS, Misses Revenue for Q4 2023
ABSI stock results show that Absci missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Absci Reports Business Updates and Fourth Quarter and Full Year 2023 Financial and Operating Results
From Absci Corporation
Via GlobeNewswire
AI-Powered Drug Discovery Stocks Index Up 9% In February; Remains Down 8% YTD
Grand View Research says the global 
Via Talk Markets
Absci Announces Closing of Public Offering of Common Stock Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
From Absci Corporation
Via GlobeNewswire
Absci Announces Pricing of Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
Absci Announces Proposed Public Offering of Common Stock
From Absci Corporation
Via GlobeNewswire
Absci Initiates IND-Enabling Studies for ABS-101, a Potential Best-in-Class Anti-TL1A Antibody de novo Designed and Optimized Using Generative AI
IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after 
From Absci Corporation
Via GlobeNewswire
Absci to Participate in Upcoming Investor Conferences
From Absci Corporation
Via GlobeNewswire
AI-Powered Drug Discovery Stocks Index Up 18% Last Week, Led By BioXcel Therapeutics
The AI-powered drug discovery market is projected to grow at a 30% CAGR between now and 2030, with annual sales in excess of $50 billion anticipated. An AI drug discovery revolution is underway. 
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Eaton Posts Strong Results, Joins Ferrari, Boot Barn And Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 share common stock offering at $1.22 per share. TransCode... 
Via Benzinga
iRobot, AST SpaceMobile And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining over 100 points on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.